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This paper addresses the epidemiology of AKI speciﬁcally in relation to recent changes in AKI classiﬁcation and revisits the
controversies regarding the timing of initiation of dialysis and the use of peritoneal dialysis as a renal replacement therapy for
AKI. In summary, the new RIFLE/AKIN classiﬁcations of AKI have facilitated more uniform diagnosis of AKI and clinically
signiﬁcant risk stratiﬁcation. Regardless, the issue of timing of dialysis initiation still remains unanswered and warrants further
examination.Furthermore,peritonealdialysisasatreatmentmodalityforAKIremainsunderutilisedinspiteofpotentialbeneﬁcial
eﬀects. Future research should be directed at identifying early reliable biomarkers of AKI, which in conjunction with RIFLE/AKIN
classiﬁcations of AKI could facilitate well-designed large randomised controlled trials of early versus late initiation of dialysis in
AKI. In addition, further studies of peritoneal dialysis in AKI addressing dialysis dose and associated complications are required
for this therapy to be accepted more widely by clinicians.
1.Introduction
In 2007, the Acute Kidney Injury Network (AKIN) replaced
the term acute renal failure with acute kidney injury (AKI)
in an attempt to include the entire spectrum of acute renal
dysfunction [1]. AKI encompasses a complex clinical entity
characterised by an abrupt decline in kidney function which
clinically manifests as azotemia, rising serum creatinine,
and in most cases oliguria. While recent advances in
renal replacement (RRT) and critical therapies have led to
improved AKI-related outcomes [2, 3], the incidence of AKI
continues to rise, possibly explained by an ageing population
with multiple comorbiditiesand an increase in sepsis-related
hospitalisations [2–7]. Furthermore, AKI continues to be
associated with signiﬁcant mortality, hospital length of stay
and economic costs, particularly in the context of critically
ill patients in the intensive care setting [5, 8–12]. Even
relatively modest absolute (≥44μmol/L) and relative (≥25%
from baseline) elevations in creatinine, have been shown to
be associated with higher mortality in hospitalised patients
[8, 11], ranging from 10% with noncritical AKI managed
outside of the intensive care unit (ICU), compared with up
to 80% with critical ICU AKI [13–16].
Although the incidence of AKI continues to rise, the
optimum management of AKI remains uncertain with no
uniform standard of care, as reﬂected by wide disparity
in clinical practice [17–19]. While multiple studies have
addressed the issue of optimal RRT modality and/or RRT
dose in critical AKI, the initiation and duration of RRT in
critical AKI remains unclear [20–24].
In this paper, we ﬁrst aim to discuss the epidemiology
and mortality outcomes of AKI across a spectrum of severity
(critical versus noncritical) as deﬁned by consensus AKI
classiﬁcations [1, 25]. Secondly, we will review the current
literature on dialysis therapies in AKI, more speciﬁcally the
indications for and optimal timing of initiation of RRT
and the role of acute peritoneal dialysis (PD). Finally, we
will provide a brief overview on the current state of novel
biomarkers of AKI and their potential future role in research
and clinical practice.
2.DeﬁnitionsofAKI:RIFLEand AKIN
Deﬁnitions for AKI vary widely between studies, ranging
fromabsoluteorrelativeincreases increatininefrombaseline2 International Journal of Nephrology
to the requirement for RRT[1, 25, 26]. The lackofa uniform
deﬁnition may explain the large diﬀerences in reported
incidence and outcomes of AKI in the literature, and as a
consequence in 2004, a consensus on the deﬁnition of acute
renal failure known as the Risk-Injury-Failure-Loss-End
stage renal disease (RIFLE) classiﬁcation was reached by a
group of international experts [25]. The RIFLE classiﬁcation
was based on two important parameters: (1) changes in
serum creatinine or GFR from baseline (2) urine output at
speciﬁc time points. The severity of acute renal failure was
determined by the more severe of the two parameters, which
were categorised into three stages. The three stages described
in RIFLE include Risk, Injury and Loss, all of which have
increasing prognostic signiﬁcance.
However, with recent studies suggesting that even minor
increments in creatinine may be associated with worse
outcomes [8], the RIFLE classiﬁcation was modiﬁed by the
Acute Kidney Injury Network (AKIN) to include (1) re-
categorisation of the original RIFLE into AKIN stage 1, 2,
and 3, (2) addition of an absolute increase in creatinine
≥26μmol/L(0.3mg/dL)tostage1criteria,and(3)automatic
classiﬁcation of patients starting RRT as stage 3, regardless of
creatinine or urine output [1]. Comparison of the old RIFLE
and modiﬁed AKIN classiﬁcation is shown in Table 1.
3.AKIEpidemiology:Criticalversus
Noncritical
Prior to employing the RIFLE/AKIN classiﬁcations, the
reported incidence of AKI in the literature varied from 1–
30%, largely due to lack of a standard deﬁnition of AKI
[2, 8, 10–12, 14–16, 27–38]. The incidence of AKI varies
according to the location of patients, either in the critical
care or noncritical care settings. The noncritical care setting
canbe further subdivided into community (data from health
district, Medicare or district hospital outpatient records),
and hospital environments (data from tertiary hospital
admissions).
In the critical care setting, the incidence of AKI ranges
from 5–20%, typically occurring in patients with severe
multiorgan failure [39]. The incidence of AKI as single-
organ failure in the ICU setting is as low as 11% compared
to 69% in non-ICU settings [13]. There have been two
large multi-centre cohort studies examining the incidence
of AKI in patients in the critical care setting. The ﬁrst
study was the Beginning and Ending Supportive Therapy
for the Kidney (BEST Kidney) which included 29,629
critically ill adult patients admitted to 54 ICUs throughout
23 countries [16]. Using a deﬁnition of AKI as oliguria
(urine output <200mL/12hrs) and/or urea >30mmol/L
(84mg/dL), the authors reported a 5.7% period prevalence
of AKI, (ranging from 1.4%–25.9% across all study centres)
usually in association with septic (47.5%) or cardiogenic
(27%) shock. Approximately two-thirds of patients who
developed AKI required RRT (4% of total cohort). The
second study was the Program to Improve Care in Acute
RenalDisease (PICARD)study.Thiswasa2-yearprospective
observational study of 618 ICU patients with AKI across 5
centers in the USA [15]. The authors deﬁned AKI as “new-
onset” by a rise in creatinine ≥44μmol/L (≥0.5mg/dL) or
“AKIonchronic kidneydisease (CKD)”as an increase in cre-
atinine ≥88μmol/L (≥1.0mg/dL) in patients with baseline
creatinine between 133μmol/L to 433μmol/L (1.5mg/dL to
4.9mg/dL). RRT was required in 64% of patients. Similar
to the BEST Kidney study, AKI occurred predominantly in
patients with multisystem organ failure. The BEST Kidney
and PICARD studies are prime examples of the variations in
reported incidence and outcomes of AKI when nonstandard
deﬁnitions of AKI are applied.
With the exception of a few studies in hospitalised
children and stem-cell transplant recipients [40, 41], the
RIFLE/AKIN classiﬁcations are seldom applied in the non-
critical care setting (i.e., hospital or community), and
variable deﬁnitions of AKI continue to confound prevalence
and incidence rates. The prevalence of hospital-acquired
AKI is thought to be approximately 5–10 times greater than
community-acquired AKI, with reported rates of AKI in 5–
7% of hospitalised patients [35, 42]. In a study of 4622
patients in a tertiary hospital, Nash et al. reported that
7.2% of patients developed “renal insuﬃciency”, deﬁned as
a4 4μmol/L increase in creatinine in patients with baseline
creatinine ≤168μmol/L, an 88μmol/L increase in patients
with baseline creatinine 177–433μmol/L, or a 132μmol/L
increase in patients with baseline creatinine ≥442μmol/L
[35]. In the Madrid Acute Renal Failure Study Group of
13 tertiary hospitals in Madrid, uNLia˜ no et al. reported
an incidence of AKI of 209 cases per million population
(pmp) as deﬁned by a sudden increase in creatinine to
level >177μmol/L (2mg/dL) in patients with normal renal
function or an increase of at least 50% from baseline
creatinine in patients with-mild-to moderate chronic renal
failure (creatinine < 264μmol/L) [34]. Preexisting renal
dysfunction was present in about 50% of patients who
developed AKI. RRT was required in 36% of patients with
AKIandwasassociatedwithahigher“severityindex”ofAKI.
Only a handful ofstudies have examined the incidence of
AKI in community settings [43] .T h eo c c u r r e n c eo fA K Ii n
the community is an infrequent event, accounting for <1%
of hospital admissions in the USA [42, 44]. Early studies
from the 1990s have reported overall annual incidence rates
of reported community-acquired AKI varying from 22–
620/million population, with most studies using need for
RRT or cutoﬀ creatinine ≥ 300 or 500μmol/L to deﬁne AKI
[45, 46]. Using changes in inpatient serum creatinine levels
to deﬁne AKI, a more recent study by Hsu et al. suggests
that the incidence of AKI in the community is increasing
over time [4]. The authors reported an increasing incidence
of nondialysis AKI and dialysis requiring AKI from 322.7 to
522.4 and 19.5 to 29.5 per 100,000 person years, respectively,
between 1996 and 2003.
Overall observational trends in both the ICU and non-
ICU settings also suggest the incidence of AKI has risen
over time, likely as a reﬂection of ageing populations
with multiple comorbidities (including chronic kidney dis-
ease),increasedinfection-relatedhospitalisationandincreas-
ing utilisation of nephrotoxic agents such as intravenous
contrast, aminoglycosides, nonsteroidal anti-inﬂammatoryInternational Journal of Nephrology 3
Table 1: RIFLE and AKIN classiﬁcation [1, 25].
RIFLE AKIN
Category Creatinine/GFR Urine output (UO) Stage Creatinine Urine output (UO)
Risk Cr increase by x1.5 times or GFR
decrease by ≥25%
UO ≤ 0.5mL/kg/hr for
6hrs Stage 1 Cr increase by x1.5
times or ≥ 26μmol/L
UO ≤ 0.5mL/kg/hr
for 6hrs
Injury Cr increase by x2 times or GFR
decrease by ≥50%
UO ≤ 0.5mL/kg/hr for
12hrs Stage 2 Cr increase by x2 UO ≤ 0.5mL/kg/hr
for 12hrs
Failure
Cr increase by x3 times or GFR
decrease by ≥75% or
Cr ≥ 354μmol/L (with acute rise ≥
44μmol/L)
UO ≤ 0.3mL/kg/hr for
24hrs or anuria for
12hrs
Stage 3
Cr increase by x3 or
Cr ≥ 354μmol/L
(with acute rise
44μmol/L) or RRT1
UO ≤ 0.3mL/kg/hr
for 24hrs or anuria
for 12hrs
Loss (outcome)
Persistent ARF = complete loss of
renal function > 4 weeks (but ≤3
months)
N/A Nil
ESRD (outcome) Complete loss of renal function > 3
months N/A Nil
RRT: renal replacement therapy.
1Patientsrequiring RRT are automaticallyconsidered stage 3 AKIN regardless of stage at time of RRT initiation.
drugs (NSAIDs) and chemotherapeutic agents [15, 42, 43].
CKDandsepsisinparticularappeartobemajorcontributors
to this process. Reports from a US hospital database estimate
that patients with CKD stage 3 (eGFR < 60mL/min per
1.73m2) have a 2-fold increase in adjusted odds ratio (OR)
ofAKI compared to CKDstages 1 and 2 (eGFR > 60mL/min
per 1.73m2), with risk progressively increasing with severity
of baseline CKD [47]. In a study of sepsis-related admissions
in US hospitals, Martin et al. noted an increase in incidence
of sepsis-related hospital admissions from 1979 to 2000
which were paralleled by increase in renal failure [7]. Studies
have shown that the risk of AKI increases accordingly with
severity of sepsis. Schrier et al. reported rates of AKI of 19%
in patients with moderate sepsis, 23% in patients with severe
sepsis and 51% in patients with positive blood cultures and
septic shock [48].
4.AetiologyofAKI:Criticalversus
Noncritical
The cause of AKI diﬀers according to patient location. Acute
tubular necrosis (ATN) due to sepsis is generally regarded as
the most common cause of AKI in the critical care setting,
accounting for up to 35–50% of all cases of AKI [13, 16,
39, 49–51]. In the BEST Kidney study, septic shock (47.5%)
was the most common aetiology of AKI, followed by major
surgery (34.3%)andcardiogenicshock(26.9%).Similarly,in
thePICARDstudy,ischaemic ATNpredominantlyattributed
to sepsis was listed as the most common aetiology of
AKI [15]. The pathogenesis of septic AKI is traditionally
thought to involve reduced renal blood ﬂow secondary
to systemic arterial vasodilatation and concomitant intra-
renal vasoconstriction, resulting in renal hypoperfusion and
ischaemia [52]. Interestingly, however, recent experimental
animal models of septic AKI have failed to support this long-
held hypothesis [53, 54]. Furthermore, in a recent systematic
review of renal histopathology in human and experimental
animal septic AKI [55], Langenberg et al. reported that only
22% of patients with septic AKI had features of ATN
on either renal biopsy or postmortem ﬁndings, with the
majority of patients having normal or only mild nonspeciﬁc
histological changes at best. Despite the limitations of this
review which include a very small sample size (117 patients),
heterogenousdeﬁnitionsofAKI,use ofpostmortem ﬁndings
versus renal biopsy, and use of relatively outdated criteria
for classic ATN, these ﬁndings suggest that ATN is relatively
uncommon in the setting of septic AKI. Further studies
evaluating the true histolopathology of septic AKI are clearly
required.
ATN is also considered the most common cause of AKI
in the hospital setting although the aetiology of ATN diﬀers
from that of critical care associated AKI. In the Madrid
Acute Renal Failure Study, ATN was documented to be the
cause of AKI in 75.9% of ICU patients compared to 37.6%
in non-ICU patients (summarised in Table 2)[ 13]. ATN
within the hospital setting is more likely to be multifactorial,
with hypotension and nephrotoxins as important causes in
addition to sepsis and surgery [42].
For community-acquired AKI, prerenal or acute-on-
chronic renal failure are common and usually occurs as the
result of dehydration or drug-related toxicities such as non-
steroidal anti-inﬂammatory drugs (NSAIDs), angiotensin-
converting enzyme (ACE) inhibitors and/or angiotensin-
receptor blockers (ARB). Elderly and patients with multiple
comorbidities such as diabetes are at particularly high risk of
developing AKI [44]. In Third World or tropical countries,
postinfectious glomerulonephritis, tropical and nontropical
infections, snake or spider bites, chemical poisons and
traditional herbal medicines are other common causes of
community-acquired AKI [42].
5.RIFLE/AKIN:ClassiﬁcationasaPrognostic
Marker in AKI
Employing the RIFLE/AKIN classiﬁcations has facilitated
improved risk stratiﬁcation in critical AKI. In a study of4 International Journal of Nephrology
1510 ICU patients, increasing mortality rates were reported
with greater severity/stages of AKI as deﬁned by RIFLE
(mortality rates of 8.8% with Risk, 11.4% with Injury, and
26.3% with Failure) [56]. In a systematic review by Ricci
et al. of 24 studies of patients with acute renal failure,
application of the RIFLE classiﬁcation was associated with
a stepwise increase in relative risk (RR) for mortality with
increasing stages of acute renal failure and across diverse
patientpopulations.Incomparisontopatientswithoutacute
renal failure, the RIFLE Risk category was associated with
RR 2.40 (95% CI 1.94–2.97) of mortality, while Injury and
Failure were associated with RR 4.15 (95% CI 3.14–5.48)
and 6.37 (95% CI 5.14–7.90) of mortality respectively [57].
Although these were retrospective studies and 12 of the 24
studies included only patients with acute renal failure/AKI
in the critical care setting, the authors concluded that RIFLE
was easily applicable to clinical practice and was a useful
tool to help stratify mortality risk in patients with AKI. In
a more recent retrospective study by Bagshaw et al. [58]o f
120,123 patients from the Australia New Zealand Intensive
Care Society Adult Patient Database (ANZICS APD), use
of the RIFLE classiﬁcation identiﬁed 36.1% of patients with
AKI out of 120,123 patient admissions to the ICU. AKI was
associated with a signiﬁcant increase in hospital mortality
compared to patients without AKI (OR 3.29; 95% CI 3.19-
3.41; P<. 0001). Similarly, each increase in the severity of
RIFLE category was also associated with a correspondingly
increased risk of hospital mortality.
StudiesutilisingtheAKINclassiﬁcationindiversepatient
populations have also demonstrated comparable ﬁndings to
studies utilising the RIFLE classiﬁcation [59–63]. In a large
retrospective study of 325,395 critically ill patients from the
Veterans Administration ICU system, the development of
AKI was associated with mortality risk (OR 2.2, 6.1, and 8.6
for AKIN stage I, II, and III, resp.) [60].
At least, six studies have directly compared the utility of
both the RIFLE and AKIN classiﬁcations in the prediction
of mortality in critical patients with AKI and ﬁve of these
studies concluded that RIFLE and AKIN were similar in
terms of diagnosing AKI and assessing mortality risk [40, 62,
64–68]. In the analysis of the ANZICS APD, Bagshaw et al.
found a less than one percent diﬀerence in the identiﬁcation
of patientswith AKIusing eitherRIFLE/AKINclassiﬁcations
within the ﬁrst 24 hours of admission to the ICU [62].
Use of the AKIN classiﬁcation slightly increased numbers
of patients with stage 1 injury (equivalent to “Risk”) from
16.2% to 18.1%, but it decreased the numbers of patients
with stage 2 injury (equivalent to RIFLE “Injury”) from
13.6% to 10.1%. The area under ROC for hospital mortality
was similar for RIFLE (0.66) and AKIN (0.67) and the
authors concluded the AKIN classiﬁcation did not further
improve the sensitivity, robustness or predictive ability of
RIFLE in the ﬁrst 24hrs of ICU admission.
6.Mortalityin AKI
AKIisassociated with extremely high mortality ratesranging
from 30-80% in the critical care setting [12, 14–16, 27, 30,
Table 2: Demographics and AKI outcomes in ICU compared to
non-ICU (Madrid Acute Renal Failure Study Group) [13].
ICU Non-ICU
Demographics and RRT
Age (mean ± SD)a 56.4 ± 16.4 yrs 62.6 ± 18.8 yrs
Malesb 72.7% 61.4%
Severity index (mean ± SD)a 0.65 ± 0.22 0.32 ± 017
Single-organ failure AKIa 11% 69%
RRTa 70.8% 18.4%
Cause of AKI
ATNa 75.9% 37.6%
Prerenalb 17.8% 28.1%
Acute-on-chronicc 7.9% 15.2%
Mortality
Unadjusted mortalitya 71.5% 31.5%
Corrected mortality 56% 15%
Mortality of single-organ
failure AKIa 30% 23%
aP<. 001.
bP<. 002.
cP<. 005.
37]. In the BEST Kidney and PICARD studies, the overall
reported mortality rateswere 60%and 37%,respectively [15,
16].
Studies have consistently observed that patients who
develop AKI have a worse mortality than patients without
AKI. Bagshaw et al. reported crude hospital mortality rates
of 42.7% and 13.4% in patients with and without AKI,
respectively (P<. 0001) [2]. Mortality of patients with
AKI is substantially increased even further in the setting of
concurrent multiorgan failures, sepsis and requirement for
RRT. Metnitz et al. demonstrated that patients with AKI
requiring RRT had signiﬁcantly higher in-hospital mortality
rates(62.8%)comparedwithpatientswithAKInotrequiring
RRT (15.6%) [12]. Similarly, Bagshaw et al. observed that
the presence of sepsis in patients with AKI (compared with
nonsepsis related AKI) was associated with greater hospital
mortality (70.2% versus 51.8%; P<. 001), severity of illness,
higher rates of multiorgan failures, a greater requirement for
ionotropic and ventilatory support, and a longer duration of
hospitalisation [69].
Althoughitis clearthatthe presenceofAKIin thecritical
care setting is associated with higher mortality and poor
prognosis, uncertainty remains as to whether AKI is directly
causal or simply a marker for greater severity of illness and
poor patient outcomes.
Evidencefor the role ofAKI as a “bystander” comesfrom
an observational cohort study of 1396 patients admitted
to the ICU showing that patients with AKI had a higher
mortality (23%) than patients with end-stage renal disease
(ESRD) (11%) and patients without AKI (5%) [70].
In contrast, other studies suggest that AKI is directly
responsible for the high mortality in this group, perhaps
through a sustained inﬂammatory response associated with
uraemia. The systemic inﬂammatory response syndromeInternational Journal of Nephrology 5
(SIRS) has been described as a nonspeciﬁc generalised
inﬂammatory response to critical illness, initially charac-
terised by systemic release of proinﬂammatory cytokines
followed by a counteranti-inﬂammatory response syndrome
(CARS) aimed at controlling and limiting this inﬂammatory
process. Disruption of these natural responses to inﬂam-
mation by clinical states such as uraemia, in which pro-
inﬂammatory and anti-inﬂammatory cytokines are released
simultaneously as opposed to sequentially, has been impli-
cated as a key mechanism in the pathogenesis of multiorgan
failure, septic shock, and death [71, 72]. Supporting this
hypothesis has been a study demonstrating that patients
with critical AKIhavesimultaneously elevatedpro- and anti-
inﬂammatory cytokines, which are independent predictors
of mortality [73]. Anti-inﬂammatory cytokines have been
shown toinducemonocytehyporesponsiveness toendotoxin
and other noxious stimuli, which may in part explain their
association with a greater severity of septic shock and
possibly poorer patient outcomes [74–76].
As with critical AKI, the presence of AKI in hospi-
talised non-ICU patients remains an important predictor
of mortality [8–11], even after allowing for confounding
variations in deﬁnitions of AKI. In the study by Nash
et al. of AKI in hospitalised patients, mortality associated
with renal failure was 19.4% [35]. Levy et al. reported
higher mortality in patients with AKI postradiocontrast
procedure(34%)comparedwithage-andbaseline creatinine
matched controls undergoing similar procedures (7%) [11].
The presence of renal failure deﬁned as an increase in
serum creatinine ≥25% from baseline to at least 177μmol/L
(2mg/dL) was associated with an adjusted mortality odds
ratio (OR) of 5.50 (95% CI 2.91–13.19; P<. 001) but the
results were confounded by the fact that no distinction was
made between AKI secondary to contrast injury or athero-
embolism, which is a common complication of invasive
angiography and associated with high mortality.
Finally, in a study of 42,773 patients undergoing cardiac
surgery, Chertow et al. reported an overall mortality of
63.7% in patients who developed AKI (deﬁned crudely as
requiring RRT within 30 days of surgery) compared to 4.3%
in patients with no AKI (adjusted OR for death 26; 95% CI
22–34) [10]. In another report of 9210 patients, Chertow et
al. demonstrated that a minor change in serum creatinine
(≥44μmol/L or 0.5mg/dL) from baseline was associated
with a 6.5-fold increased risk of death (95% CI 5.0–8.5) [8].
7.MortalityComparisonsbetweenCritical
AKIand NoncriticalAKI
While it is widely accepted that mortality associated with
critical AKI is higher than noncritical AKI, this may be
related to associated multiorgan failure seen in the critical
care setting. In a followup study from the Madrid Acute
RenalFailureStudyGroup,Lianoet al.prospectivelyassessed
the outcomes of 748 individual AKI episodes comprising
of 253 ICU cases and 495 non-ICU patients (results sum-
marised in Table 2)[ 13]. The authorsreported a signiﬁcantly
higher crude mortality in ICU-associated AKI (71.5%)
comparedwithnon-ICUAKI(31.5%)overa9monthperiod
(P<. 001). However, AKI in the absence of multiorgan
failure (i.e., isolated AKI) was rare in the critical care
setting compared with the noncritical care setting (11% ICU
versus 69% non-ICU; P<. 001) but mortality in patients
with isolated AKI was comparable between those treated in
the critical and noncritical settings (30% ICU versus 23%
non-ICU; P = NS). Furthermore, analysis of patients with
AKI in the presence of multiorgan failure demonstrated
a signiﬁcant linear increase in mortality with increasing
number of organ failures, regardless of the location of the
patients. The use of RRT was associated with signiﬁcantly
higher mortality in both critical care (79.3% versuss 53%;
P<. 001) and noncritical care settings (40% versus 30%;
P<. 001). It remains debatable as to whether use of RRT
was directly responsible for the increased mortality, possibly
by enhancing the patient’s inﬂammatory responses.
In a separate retrospective study of 114 patients with
dialysis-requiring AKI, Routh et al. reported that there was
no association between critical AKI and mortality [77].
Although overall patient survival was signiﬁcantly lower
in critical care compared with noncritical care patients
(36% versus 63%; P<. 01), the authors suggested the
discrepancy in survival between patient groups was related
to the severity of the precipitating illness and concluded
that aggressive supportive care was suﬃcient to eliminate
the “morbidity and mortality due to ARF per se”. However,
a signiﬁcant limitation of this study was that AKI was
deﬁned as having at least one dialysis session in addition
to “standard clinical and biochemical criteria” which were
not speciﬁed. In addition to this, patients in this study were
younger compared to patients in more recently published
literature, preexisting comorbidities were not recorded and
dialysis technologies were signiﬁcantly diﬀerent during the
study period (1969–1978) compared to the present day.
Furthermore, the applicability of this data to current clinical
practice is not clear given the trends towards increasingly
complex patient disease states and changes in treatment
technologies over the last 40 years.
Thus, while mortality is greater in patients with critical
AKI compared with noncritical AKI, this may reﬂect the
severity of the underlying illness. Patients with isolated
single-organ AKIappeartohaveabetterprognosiscompared
topatientswithAKIinthepresenceofmultiorganfailureand
regardless of location, patients with AKI requiring RRT have
signiﬁcantly higher mortality than do patients with AKI that
do not require RRT.
8.AcuteKidneyInjury: Current
Controversies
AKI is highly prevalent and is associated with considerable
morbidity and mortality, particularly in critically ill patients.
D e s p i t et h i s ,t h eo p t i m a lu s eo fR R Tf o rA K Ir e m a i n su n c l e a r
and has been plagued by controversies which include the
optimal timing for initiation of RRT, modality (intermittent
haemodialysis (HD) versus continuous renal replacement
therapy (CRRT)) and dosing [78].6 International Journal of Nephrology
The issue of optimal RRT dose has only recently been
better deﬁned by two large multicentre prospective ran-
domised controlled trials; the VA/NIH Acute Renal Failure
Trial Network (ATN) study in the USA and the Randomised
Evaluation of Normal versus Augmented Level Replacement
Therapy (RENAL) study in Australia and New Zealand
[23, 79]. These landmark trials were designed to compare
“less intensive” to “intensive” RRT and both failed to
demonstrate a survival beneﬁt with higher CRRT doses
beyond the current conventional dose of 25mL/kg/hr in
critically ill patients with AKI. Furthermore, with CRRT
doses <20mL/kg/hr, a dose-response relationship towards
worse patient outcomes is likely to exist [78, 80]. This last
ﬁnding has important implications, given that 46.4% and
18% of patients from international surveys such as the BEST
Kidney and Do-Re-Mi studies reportedly received a CRRT
dose of <20mL/kg/hr [19, 81]. Given that there are often
discrepancies between prescribed and delivered CRRT doses
as highlighted by the RENAL and ATN trials (delivered dose
10–15% lower than prescribed), it is advisable that clinicians
adjust RRT prescription accordingly [78, 80].
The lack of survival beneﬁt with increased RRT dosing
places even more importance upon other aspects of RRT,
such as the optimal timing for initiation of RRT, as we
continuetoseekimprovementsincurrentAKIoutcomesand
is discussed below.
9.FactorsAffectingRRTInitiation
For patients with AKI, the timing and rationale for initi-
ation of RRT varies between critical care and noncritical
care settings. In the noncritical care patient with AKI,
RRT is regarded as a supportive therapy to be used for
prevention of acute uraemic complications. Traditional
indications for RRT have been based on criteria used
for ESRD patients, such as refractory ﬂuid overload or
hyperkalaemia, severe metabolic acidosis, overt uraemia
(pericarditis/encephalopathy/neuropathy) or symptomatic
progressive azotaemia [24, 95].
However,thisapproach maynotbeappropriateinassess-
ing the requirement for RRT in patients with critical AKI,
particularly in the setting of multiorgan failure [82]. Thus,
in contrast, the rationale for initiation of RRT in patients
with critical AKI includes factors outside the traditional
paradigm described above. Table 3 summarises the relative
and absolute recommendations for dialysis [82, 96].
Cruz et al. suggest that the presence of speciﬁc “criti-
cal” conditions should be considered prior to determining
whether to initiate RRT in patients with critical AKI.
Examples given by the authors include clinical syndromes
associated with high catabolic states such as septic shock,
burns, or trauma or in other high “metabolic” scenarios
such as gastrointestinal bleeding or rhabdomyolysis which
often place a greater demand upon renal reserve [97].
Furthermore, based on studies demonstrating an association
between positive ﬂuid balance and worse outcomes in
critically ill patients with AKI, sepsis, acute lung injury
(ALI) and postsurgery, ﬂuid balance management has been
identiﬁed as another important consideration in the man-
agement of patients in the critical care setting [98–104].
It has been hypothesised that ﬂuid overload results in
accumulation of ﬂuid in the extracellular compartment due
to leaky capillaries. This thenleads tovisceral oedema, which
in turn promotes intra-abdominal hypertension and renal
interstitialoedema,bothofwhichmayperpetuateAKI[105].
Finally, there is growing data suggesting an important role
of the kidneys in the clearance of inﬂammatory molecules,
which may be critical in the pathogenesis of ALI and acute
respiratory distress syndrome(ARDS)aswellasprecipitating
and/or exacerbating AKI [106]. While the “criteria” for
initiation of RRT based on hypercatabolic states, speciﬁc
clinical states, ﬂuid status and a pro-inﬂammatory state
remain unclear, these data may be seen to favour earlier
initiation of RRT compared with traditional indicators for
RRT.
10.TimingofInitiationofRRT—Haemodialysis
At present, there is no consensus regarding when to initiate
RRT,resultingin awidevariation inclinicalpractice[17,18].
A major barrier towards determining the optimal timing
for RRT initiation has been the lack of agreement over the
absolute indications for RRT. A review by Palevsky in 2008
highlighted a few common scenarios of AKI in a critical care
setting, whereby the decision for RRT is debatable [24]. It
remains unclear whether there is survival beneﬁt in early
consideration of RRT in the management of asymptomatic
oliguric patients with progressive azotemia or in those with
diuretic-resistant renal failure. Furthermore, there are no
deﬁnitive criteria regarding what levels of hyperkalaemia,
acidosis, oliguria or urea/creatinine are acceptable before
RRT is initiated for survival beneﬁt. As many of these
“criteria” for RRT are based upon physician beliefor practice
and are derived from studies in ESRD patients, one could
question their applicability to AKI patients. Thus, the
recommendations published by the Acute Dialysis Quality
Initiative (ADQI) for RRT initiation in AKI should be
regarded as guidelines only [107]. Moreover, decisions on
initiating dialysisin patientswithAKImayalsobeinﬂuenced
by nonmodiﬁable orexternal factors, includingage, presence
of comorbidities, resource availability, cost and physician
preference [24]. A summary ofthe studiescomparing timing
of RRT is presented in Table 4 and discussed below.
Despite the presence of several studies attempting to
address the optimal timing of RRT in patients with AKI
[84–94, 108, 109], their interpretation should take into
accountthelargeheterogeneouspopulationsinthesestudies.
Most of the studies are retrospective observational data in
which causality between timing of RRT in AKI and outcome
cannot be established, and many of the prospective studies
have methodological ﬂaws, insuﬃcient sample size and are
therefore, underpowered to detect a diﬀerence between
groups. The lack of a clear-cut deﬁnition for AKI, including
what constitutes “early” and “late” initiation of RRT further
compounds the diﬃculties in interpreting the data. Finally,
an inherent methodological ﬂaw in the literature is thatInternational Journal of Nephrology 7
Table 3: Recommended relative and absolute indications for RRT in critically ill patients with AKI [82].
Dialysis indication Criteria Absolute/relative
Metabolic
Urea > 27mmol/L Relative
Urea > 35.7mmol/L Absolute
Hyperkalaemia > 6mmol/L Relative
Hyperkalaemia > 6mmol/L plus ECG changes Absolute
Dysnatraemia Relative
Hypermagnesaemia > 4mmol/L R elative
Hypermagnesaemia > 4mmol/L plus anuria or
areﬂexia Absolute
Acidosis pH > 7.15 Relative
pH < 7.15 Absolute
Anuria/oliguria
Risk (RIFLE class) Relative
Injury (RIFLE class) Relative
Failure (RIFLE class) Relative
UO < 200mL for 12hrs or anuria Absolute
Uraemic complication
Encephalopathy Absolute
Pericarditis Absolute
Myopathy Absolute
Neuropathy Absolute
Bleeding Absolute
Fluid overload Diuretic responsive Relative
Diuretic resistant (with pulmonary oedema) Absolute
studies have been limited to patients receiving RRT, thus
excluding the patient group with AKI who die or recover
without RRT. Therefore, any observed beneﬁt of early RRT
may be subject to bias by indication, as this may be due to
inclusion or exclusion of patients with less severe illness and
better prognosis regardless of treatment received.
Earlier studies using various cutoﬀ values of serum urea
and creatinine or urine output as criteria for initiation
of dialysis regarded commencement of RRT at urea levels
>75mmol/L as late initiation of RRT, a level considered
unacceptably high by current standards [83, 84]. In contrast,
more recent studies deﬁne late initiation as a predialysis urea
>25–28mmol/L at time of RRT commencement [89, 94].
However, the reliance on urea, creatinine and ﬂuid
status/urine output as indicators for initiation of RRT in
patients with AKI is controversial. In particular, serum urea,
and creatinine are not true markers of kidney injury, require
time to accumulate before detection at abnormal levels (48–
72hrs), and are often inﬂuenced by nonrenal factors such as
muscle mass, rhabdomyolysis, gastrointestinal haemorrhage
and drugs such as corticosteroids [110].
The timing of RRT in patients with AKIwas ﬁrst assessed
by Teschan et al. in 1960, who evaluated the eﬀects of “pro-
phylactic” haemodialysis in patients with oliguric AKI [109].
In this case series, the mortality rate of patients with AKI in
whom RRT was initiated prior to the urea reaching a level
of 71.4mmol/L was 33%. This compared favourably with
a reported mortality rate of 25–40% in historical controls.
Subsequent reports were based on retrospective case series
comparing the eﬀects of early to late RRT initiation over
ad i v e r s er a n g eo fu r e ac u t o ﬀ levels (35–75mmo/L), all of
which suggested improved survival with early RRT [83–85].
Retrospective studiescomparing early to late initiation of
RRT have generally favoured early RRT. In a retrospective
single-center study of 100 trauma patients, patients who
developed AKI and received early initiation of RRT (urea
< 22.5mmol/L, mean urea at RRT initiation of 15mmol/L)
had improved survival (39% versus 20%; P = .041)
compared with patientsreceiving late initiation ofRRT(urea
≥ 22.5mmol/L, mean urea at RRT initiation of 34mmol/L;
P<. 0001) [88]. A greater proportion of patients in the late
initiation group had multiorgan failure and sepsis, but there
were more oliguric patients in the early group (56%) than
t h el a t eg r o u p( 3 9 % ;P<. 01). Furthermore, the rationale for
starting RRT in the early or late ungroups was unclear. Two
retrospective single-centre studies have compared initiation
of RRT early (urine output < 100mL for 8 hrs) or late (based
on conventional biochemistry parameters) in postcardiac
surgery patients with AKI. Both Elahi et al. (22% versus
43%; P<. 05) and Demirkilic ¸ et al. (23.5% versus 55.5%;
P = .016)reportedthatearlyinitiationofRRTwasassociated
with lowermortality. Themean timetoinitiationofRRTwas
signiﬁcantly diﬀerent between early and late groups for both
studies [90, 91].
Timing of RRT has also been assessed in ICU patients
with septic shock and oliguric AKI. In a retrospective single-
centre study, Piccinni et al. compared early initiation of
RRT within 12 hrs of ICU admission (n = 40) to late
initiation of RRT for conventional indications in historical
controls (n = 40) [92]. Early initiation was associated with8 International Journal of Nephrology
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Table 5: Time to RRT initiation, predialysis urea and patient cohort survival from Bouman et al. [89].
Early high volume Group
(n = 35)
Early low volume Group
(n = 35)
Late low volume Group
(n = 30)
Time between inclusion and ﬁrst RRT (hrs) 6.0 (3.0–9.7) 7.0 (5.0–10.0) 41.8 (21.4–72.0)a
Predialysis urea before ﬁrst RRT (mmol/L) 16.3 (13.7–20.6) 17.1 (14.4–23.5) 37.4 (22.0–41.4)a
Survival (%)b 74.3 68.8 75.0
Data presented as median and interquartile ranges.
aP<. 001 between late low volume group and early groups.
bP = .8 between groups.
improved 28-day survival (55% versus 27.5%; P<. 05), gas
exchange, haemodynamics and ventilatory wean. However,
information onthe time between onset of AKI and initiation
of RRT was not provided and patients in the late RRT group
received a lower dialysis dose.
In a cohort of 98 patients with AKI after major
abdominal surgery from the National Taiwan University
Surgical ICU Associated Renal Failure (NSARF) Study
Group database, Shiao et al. retrospectively applied a sim-
pliﬁed RIFLE classiﬁcation (use of GFR criteria only) to
stratify patients receiving early (RIFLE-0/Risk) and late
(Injury/Failure) RRT[108]. During the study period, indica-
tions for RRT were azotemia with uraemic symptoms (urea
> 28mmol/L and creatinine > 177μmol/L), oligoanuria
(urine output < 200mL/8hrs), refractory ﬂuid overload,
hyperkalaemia (K>5.5mmol/L) and metabolic acidosis
(pH < 7.20). About 80% of patients commenced RRT for
azotaemia or oligoanuria and 52% were classiﬁed into the
early RRT group. Early initiation of RRT was associated with
lower in-hospital mortality (43.1% versus 74.5%; P = .002)
and predictors of mortality included late RRT (hazard ratio
(HR) 1.846; P = .027), old age, cardiac failure and pre-RRT
Sequential Organ Failure Assessment (SOFA) score. A major
limitationofthis study was that theRIFLE classiﬁcationused
and criteria for initiation of RRT were discrete and separate
scoring systems. Therefore the validity of applying RIFLE to
stratify intoearly orlate RRTisquestionable,especially given
that urine outputcriteria were used in one and not the other.
Initial prospective trials purporting to compare early
versus late dialysis can be criticised for having only achieved
a comparison between intensive and non-intensive dialysis
dose. In a small cohort of 18 patients with post-traumatic
AKIduring the Vietnam War [86], patients were matched on
the basis of similarity of injuries and assigned sequentially
and alternately to “intensive” dialysis to maintain a predial-
ysis urea < 26mmol/L and creatinine < 442μmol/L, or to
“non-intensive” dialysis in which RRT was initiated only
when clinically indicated or if the urea and creatinine levels
reached 56mmol/L or 884μmol/L, respectively. This latter
group was assumed to have delayed initiation of dialysis,
although details regarding time to initiation of dialysis
were not provided. There was a trend toward improved
survival in the intensive dialysis compared to non-intensive
groups (64% versus 20%; P>. 05) in this small study.
However, these diﬀerences are more attributable to dose
of dialysis rather than timing of initiation. Similarly, in a
larger prospective controlled trial involving 34 patients with
critical AKI, Gillum et al. randomised patients with AKI
to intensive haemodialysis targeting a maximum predialysis
urea 22.5mmol/L and creatinine 442μmol/L, respectively,
compared with non-intensive haemodialysis targeting a
maximum predialysis urea and creatinine of <37.5mmol/L
and 795μmol/L, respectively, [87]. While the mortality rates
between intensive and non-intensive groups were similar
(58.8% versus 47.1%; P<. 0 5 ) ,t h ea v e r a g et i m ef r o mo n s e t
of AKI until initiation of dialysis was similar between the
intensive and non-intensive groups (5 ± 2d a y sv e r s u s7±
3d a y s ;P value not provideed), and thus, the study failed
to examine the eﬀect of timing of initiation of dialysis. The
authors concluded that there was no advantage of intensive
dialysis in this cohort of patients. As the blood urea and
creatinine prior to initiation of dialysis were similar in both
groups, no comment can be made regarding the eﬀect of
timing of initiation of dialysis.
Bouman et al. randomised 106 critically ill patients
requiring ventilator and ionotropic support with AKI into 3
groups: (1) early high-volume CVVHDF (n = 35), (2) early
low-volume CVVHDF (n = 35), and (3) late low-volume
CVVHDF (n = 30) [89]. AKI was deﬁned as creatinine
clearance < 20mL/min and urine output < 180mL over
6hrs despite volume resuscitation. In the early group RRT
was commenced within 12hrs of diagnosis of AKI. In the
late group, RRT was initiated when urea > 40mmol/L or
severe pulmonary oedema occurred. The median times and
predialysis urea before ﬁrst RRT sessions are summarised
in Table 5. There were no signiﬁcant diﬀerences in 28-day
survivalacrossthe3groups(74.3%versus68.8%versus75%;
P = .80) and renal function recovered in all survivors at
hospital discharge exceptonepatientintheearly low-volume
group. While this study achieved signiﬁcant separation in
timing of initiation of early versus late dialysis and suggests
that timing of initiation and dose of dialysis had no eﬀect on
outcome,there were signiﬁcant limitations to this study. Late
RRT was not as late in comparison to other studies. Fifteen
patients in the late group (50%) commenced RRT with urea
< 40mmol/L due to severe pulmonary oedema and the early
group did not receive RRT as early as originally planned
due to the requirement for measured creatinine clearance
< 20mL/min before inclusion. Furthermore, the overall
mortality rate of 27% was unexpectedly low, reﬂecting
possibly a lower disease burden within the patient cohort.
Data from prospective observational studies on timing
of RRT is also conﬂicting. In a multicentre study based on
PICARD, Liu et al. assessed the eﬀects of timing of initiation10 International Journal of Nephrology
of dialysis in 243 patients with severe AKI and no pre-
existing CKD [93]. Patients were stratiﬁed into early (urea
≤ 28.5mmol/L; n = 122) or late RRT (urea > 28.5mmol/L;
n = 121) groups based on urea at initiation of RRT. Late
initiation of RRT was associated with an increased relative
risk death (RR 1.85; 95% CI 1.16–2.96) in comparison to the
early group, despite a lesser burden of organ failures.
In a large prospective observational multicentre study
from the BEST Kidney cohort, Bagshaw et al. compared
early versus late initiation of RRT according to urea
(24.2mmol/L), creatinine (309μmol/L) and time after ICU
admission (early <2 days, delayed 2–5 days, late >5d a y s )
in 1238 patients with AKI requiring RRT [94]. Stratiﬁcation
of RRT timing by urea level showed similar mortality for
early and late initiation (63.4% versus 61.4%; OR 0.92; 95%
CI 0.73–1.15; P = .48), but when stratiﬁed by creatinine,
late initiation of RRT was associated with lower mortality
(71.4% versus 53.4%; OR 0.46; 95% CI 0.36–0.58; P<. 001).
When assessed for timing relative to ICU admission, late
RRT was associated with higher mortality than delayed or
early RRT,respectively, (72.8%versus62.3%versus59%;P<
.001), as well as longer duration of RRT, hospital stay, and
greater rates of dialysis dependence. The authors argued the
unreliability of AKI biomarkers such as urea and creatinine
which vary with clinical states such as ﬂuid overload, GI
haemorrhage and muscle mass. They felt that this study
supported early initiation of dialysis therapy as deﬁned as
time from ICU admission for AKI until such time as more
reliable biomarkers of renal injury are available to facilitate
early and accurate diagnosis of AKI.
Although not designed to assess the eﬀects of timing
of RRT, data from the RENAL and ATN studies have also
suggested similar ﬁndings with regards to late dialysis as
deﬁned by days from time of ICU admission [78]. RRT
was commenced much earlier in the RENAL study than
the ATN study (median time from ICU admission to ﬁrst
RRT 2.1 days vrsus 6.7 days). However, just over 60%
of patients in the ATN study had received some form of
RRT prerandomisation (0% in RENAL) and predialysis urea
levelsbeforeRRTinitiationweresimilar(24.2mmol/Lversus
23.8mmol/L) in the RENAL and ATN studies respectively.
Mortality in the RENAL study was lower (45% mortality at
90 days) than that of the ATN study (53% mortality at 60
days) and the rate of renal recovery or RRT independence
in survivors at 28 days was far superior in the RENAL
study (87% versus 55%). Similar diﬀerences in favour of
the RENAL study are noted when comparisons of renal
outcomes at day 60 and 90 between the two studies are
made. However, other factors such as diﬀerences in patient
populations or treatment-related factors between the two
trials could account for these ﬁndings. For example, 100%
of patients received CRRT in the RENAL trial, while 30% of
patients in the ATN trial were treated with intermittent HD
asthe ﬁrst RRTofchoice.Therefore, no ﬁrm conclusionscan
be drawn at present.
Finally, a recent meta-analysis of the timing of RRT in
patients with AKI has reviewed 23 studies, (5 randomised or
quasirandomised trials and 1 prospective and 16 retrospec-
tive cohort studies) butdid not includethe more recent large
prospective trial by Seabra et al. [111]. When analysis was
conﬁned to randomised trials, early RRT was associated with
a36%reductioninmortality,butthisdidnotreachstatistical
signiﬁcance. In cohort studies, with larger sample size, early
RRT was associated with a signiﬁcant 27% reduction in
mortality risk which did reach statistical signiﬁcance. Due
to the signiﬁcant heterogeneity between studies (including
use of multiple deﬁnitions of RRT) and possible publication
bias, the authors concluded that while early initiation of
RRT in AKI might be associated with better patient survival,
the results were inconclusive and larger adequately powered
studies were required.
Therefore, theliteratureontiming ofinitiation ofdialysis
has signiﬁcant limitations and although recent studies sug-
gest that early RRT may be associated with better outcomes,
n od e ﬁ n i t i v ec o n c l u s i o n sc a nb em a d e .C u r r e n t l y ,t h ed e c i -
sions on initiation of RRT must be made within the context
of each patient, taking into account age, comorbidities,
severity of illness and overall clinical state.
11.PeritonealDialysis (PD) andAKI:
CurrentStatus
Compared with HD/CRRT,PD is often overlooked as a form
of RRT for AKI in developed countries. In the BEST Kidney
study,PDwasutilisedinonly3.2%ofpatientsrequiringRRT,
compared to 80.2% and 16.9% for CRRT and intermittent
HD, respectively, [16]. However, driven by resource avail-
ability, PD is often the only option available for treatment
of AKI in developing countries, with potential beneﬁts that
include ease of administration, technical simplicity, low
bleeding risk, cardiovascular stability, and the absence of an
extracorporeal circuit. Furthermore, PD has proven to be a
vital resource in situations of natural disaster and massive
crush injury whereby basic infrastructure requirements such
as adequate power, water supply and manpower are often
unavailable [112]. Finally, the use of PD in AKI may be
associated with more rapid renal recovery, as suggested by
a randomised controlled trial reporting that high volume PD
(HVPD) was associated with a signiﬁcantly shorter time to
recovery of renal function (7.2 ± 2.6 days) compared with
daily HD (10.6 ± 4.7 days; P = .04) [113]. The potential
for more rapid recovery of renal function is an attractive
but relatively unstudied beneﬁt of PD which warrants future
investigation. Although only observational data on this
aspect of PD and AKI exist, there is biological plausibility
given that PD is associated with superior preservation of
residual renal function in ESRD patients [53, 114], and is
considered a less inﬂammatory, more physiological form of
RRT characterised by greater cardiovascular stability and
absence of negative phenomena such as myocardial stunning
[78, 79, 115, 116].
The declining use of acute PD in developed countries is
predominantly the result of a widely held perception that
PD fails to achieve adequate solute clearance, particularly in
hypercatabolic patients [117, 118]. Consequently, the lack of
exposure to acute PD has further compounded the situation,
resulting in a growing loss of physician familiarity with PDInternational Journal of Nephrology 11
prescription for AKI, techniques, complications and access
issues. Other perceived shortcomings of acute PD include
the technical expertise required for PD catheter insertion,
prerequisite requirement for an intact peritoneal membrane
which precludes patients with major abdominal surgery
or trauma, risk of peritonitis, protein loss, hyperglycaemia
potential for diaphragmatic splinting and inferior ﬂuid
balance control [119]. However, limited studies of PD
and AKI in selected patients have not reported signiﬁcant
problems with ultraﬁltration, hyperglycaemia, or protein
loss, and report peritonitis rates that are comparable to
catheter infection rates in patients receiving daily HD [113,
120].
12.PeritonealDialysis and AKI—Dose and
Small SoluteClearanceandTechniques
Inadequate clearance and RRT dose in critically ill patients
with AKI is associated with worse outcomes [121–123].
Unfortunately, the issue of RRT dosing and clearance in
acute PD is fraught with controversy. Firstly, there is no
consensus on target RRT dose in AKI. Secondly, no studies
have examined the eﬀects of diﬀerent doses of acute PD on
outcomes in AKI. Target doses have instead been inferred
fromstudiesbasedonHD/CRRT.Thirdly,whilstRRTdosein
AKIistraditionallymeasuredassmall-solute(i.e.,urea)clear-
ance, the validity of urea kinetic modelling and the derived
Kt/Vurea formula is questionable given that it was originally
designed for use in ESRD patients. Speciﬁc criticisms of
the application of Kt/Vurea to unstable patients with AKI
include the inherent unreliability of urea in hypercatabolic
states, diﬃculties in accurately determining volume of urea
distribution (often underestimated), and the requirement
for a steady state (usually 6 weeks after starting dialysis in
ESRD) [124, 125]. However, despite the limitations outlined
above, standardised Kt/Vurea remains the most commonly
used measure of dose for all dialysis modalities in AKI due
to lack of better alternatives.
Based on a prospective study from the Cleveland Clinic
Foundation (CCF), the accepted minimum RRT dose for
AKI is a single pool Kt/Vurea of 1.0 per session, which
is equivalent to a standardised Kt/Vurea of 2.10 per week
(assuming 3-4 sessions of intermittent HD per week) [121].
In this nonrandomised cohort of 844 ICU patients with AKI
and requiring ﬁrst time RRT (intermittent HD), improved
survival was observed in patients receiving Kt/Vurea > 1.0
per HD session. Despite conﬂicting results from subsequent
trials by Schiﬄ et al. [123]a n dP a l e v s k ye ta l .[ 23], a
standardised Kt/Vurea of 2.10 is now also regarded as an
acceptable minimum target dose of PD for AKI [119].
However, it must be remembered that this is a general
recommendation only and not a ﬁxed target for all patients,
as ultimately the optimal RRT dose for AKI remains unclear.
Selection of an appropriate PD technique is vital for
achieving adequate solute clearance and various techniques
from chronic PD have been adapted and applied to AKI
[126]. Use of ﬂexible PD catheters and techniques such
as continuous PD (CPD), tidal PD (TPD) and HVPD
have demonstrated the ability to achieve adequate solute
clearances.
CPD is similar to continuous ambulatory PD (CAPD)
in ESRD patients, in that it involves long 2–6hr dwells
of up to 2L dialysate (roughly 4 exchanges/day) [127].
TPD consists of an initial infusion of dialysate (usually 2L
volume)into the peritoneal cavity. This is followed by partial
drainage (50%) of the dialysate (tidal drain volume) which
is then replaced by fresh dialysate (tidal ﬁll volume). Thus
a reserve volume of dialysate perpetually remains in the
peritoneal cavity for the duration of the tidal cycle. TPD is
aimed at improving dialysis eﬃcacy by minimising time lost
during dialysate outﬂow, increasing dialysate ﬂow rate, and
facilitating greater middle molecule clearance by allowing
a longer duration of dialysate contact with the peritoneum
[128]. In a randomised cross-over study, Chitalia et al.
reported a standardisd Kt/Vurea of 1.80 ± 0.32 and 2.43 ±
0.87 for CPD and TPD, respectively [118].
HVPD is a form of continuous PD therapy designed
to achieve high small solute clearance through frequent 2L
exchanges (18–48 exchanges/day) via a ﬂexible Tenkhoﬀ
catheter and automated cycler (total dialysate volume 36–
70L/day) [129]. In a prospective study of 30 patients
with AKI, Gabriel et al. reported a delivered standardised
Kt/Vurea of 3.85 ± 0.62, using about 36–44L dialysate/day.
Ultraﬁltration volume was also adequate at 2.1 ± 0.62L/day,
and serum albumin levels remained stable [129].
13.PeritonealDialysis andAKI—Middle
Molecule Clearance
With recent shifts in philosophy towards middle molecule
clearance(500–2000Da)inAKI[130],PDmaybepotentially
advantageous overHD,asit isgenerallyassumed thatmiddle
clearance is superior with PD [131]. However, this may no
longer be true with modern-day use of high ﬂux synthetic
dialysis membranes [132], and there are no studies available
on middle molecule clearance in acute PD. Peritoneal clear-
ance of middle molecules is dependent on both convection
and diﬀusion and is largely determined by the dialysate dwell
time [133]. Therefore, increased frequency of exchanges to
improve small molecule clearance may impact negatively
upon middle molecule clearance in acute PD. Furthermore,
the peritoneum is a complex biological entity which actively
metabolises and secretes proteins, and this may result in
clearance of very diﬀerent types of middle molecules in
comparison to dialysis membranes and ﬁlters. Currently,
dialysis dose remains determined largely by small solute
clearance with no recommendations for middle molecule
clearance, and it is suggested that continuous forms of PD
therapy which avoid “dry” dwell times such as HVPD be
employed for treatment of AKI [119].
14.PeritonealDialysis andAKI—Comparison
to HD/CRRT
There are very few head-to-head comparison of PD and
HD in AKI, and the results suggest that with use of correct12 International Journal of Nephrology
technique, PD is comparable to HD except in one study.
Phu et al. randomised patients with AKI requiring dialysis
secondary to sepsis/malaria to haemoﬁltration (n = 34)
or PD (n = 36) [134]. PD was administered via a rigid
catheter with use of 2L exchanges and 30 minute dwell
times (total approximately 70L/day) and an average dialysis
session length of 26hrs. Dialysis dose and solute clearances
were not reported. Compared to haemoﬁltration, PD was
associated with increased mortality (47% versus 15%; P =
.005), risk of death (OR 5.1; 95% 1.6–16), and increased
risk of requiring future dialysis (OR 4.70 95% CI 1.3–17).
The authors concluded that haemoﬁltration was superior
to PD for treatment of infection-associated AKI. However,
this study had signiﬁcant limitations including the use of
a rigid cathether, PD exchanges being performed manually
with short dwell times, the use of PD solutions which were
prepared by the hospital pharmacy and no comparison of
dialysis dose or clearance across the diﬀerent modalities.
Gabriel et al. compared both CPD (n = 60) and HVPD
(n = 60) to daily HD (n = 60) in two separate randomised
trials [113, 135]. In the ﬁrst study comparing CPD and
daily HD, standardised Kt/Vurea was signiﬁcantly lower with
CPD compared to HD (3.59 ± 0.61 versus 4.76 ± 0.65;
P<. 01). There were no diﬀerences in metabolic control,
survival (58% versus 52%; P = .48) or dialysis dependence
at 30 days (17% versus 21%; P = .45) between CPD and
HDgroups,respectively.However,patientsintheCPDgroup
had a shorter duration of therapy (5.5 days versus 7.5 days;
P = .02) [135]. Similarly in the second study comparing
HVPD and daily HD, standardised Kt/Vurea was lower with
HVPD in comparison to HD (3.6 ± 0.6 versus 4.7 ± 0.6;
P<. 01). Metabolic control, mortality (58% versus 53%;
P = .71) and recovery of renal function at 30 days (83%
versus 77%; P = .45) were similar between the HVPD and
daily HD groups. Once again, HVPD was associated with a
signiﬁcantly shorter time torecovery ofrenal function (7.2 ±
2.6 days versus 10.6 ± 4.7 days; P = .04) [113].
15. FutureDirections: Novel AKI Biomarkers
Biomarkers were initially discovered with use of screening
cDNA microarray technology, which identiﬁed several gene
subsets undergoing rapid upregulation within hours of
initial renal injury [136, 137]. Our current understanding
of biomarkers is that two groups exist: (1) proteins/enzymes
which are normal constitutes of renal tubular epithelial
cells and are released into the urine as a result of cellular
injury (e.g., cystatin C), and (2) inducible proteins which are
upregulated in response to cellular injury and are otherwise
not normally present (e.g., neutrophil gelatinase-associated
lipocalin).
A recent 2008 systematic review has identiﬁed sev-
eral serum and urinary biomarkers including neutrophil
gelatinase-associated lipocalin (NGAL), cystatin C (CysC),
interleukin-18, kidney injury molecule-1 (KIM-1) and N-
acetyl-β-D-glucosaminidase (NAG), with promising utility
for early diagnosis of AKI, diagnosis of established AKI and
prediction of outcomes from AKI (requirement for RRT
and mortality). However, several issues remain and these
biomarkers require further validation in large studies of
heterogenous populations, particularly with regards to the
applicabilityofbiomarkerstodiﬀerenttypesofAKIandtheir
additional prognostic value over and above currently used
clinical parameters [138]. In additionto this, recent evidence
suggests that the predictive ability of biomarkers for AKI is
reduced in patients with CKD (baseline eGFR < 60mL/min
per 1.73m2)[ 139].
As an example, NGAL is highly sensitive for the early
diagnosis of AKI in children undergoing cardiac surgery
and patients undergoing renal transplantation [140, 141].
Plasma NGAL is also predictive of the requirement for RRT
in critically ill adult patients with AKI in the ICU [142].
However, when applied to more heterogenous populations
such as the emergency department [143], adults undergoing
cardiac surgery [144], and both adults or children in the
ICU [142, 145, 146], the ability of NGAL to detect AKI early
is reduced. Furthermore, there is evidence suggesting that
NGAL is elevated in the presence of sepsis, multiple pre-
existingcomorbiditiesandaccordingtotheseverityofillness,
thus confounding its association with AKI [142, 145, 146].
Therefore, further research is required to validate these
biomarkers, and ultimately, it would seem that a biomarker
panel for AKI which utilises the strengths of each biomarker
isrequiredtoaccuratelyidentifypatientswithAKIinatimely
fashion to allow risk stratiﬁcation and predict outcomes and
the need for RRT. In the research setting and in conjunction
with the RIFLE/AKIN classiﬁcation, biomarkers of AKI may
assist in identifying patients at risk of AKI at an earlier stage
andmayallowclearerdelineationofearlyversusdelayedtime
points for initiation of RRT which can then be applied in a
prospective randomised controlled trial.
16.Summary
Standardised deﬁnitions for AKI, namely, the RIFLE/AKIN
classiﬁcations, are an essential tool for understanding
the epidemiology, aetiology, appropriate management, and
prognosis of AKI. Critical and noncritical AKI is highly
prevalent with a rising incidence and is associated with high
mortality, particularly in the ICU setting. The RIFLE/AKIN
classiﬁcations have been shown to be good prognostic tools
for morbidity and mortality associated with AKI.
The key management controversy in relation to AKI lies
around the timing of initiation of RRT.Based on current evi-
dence, the optimal timing for initiation of RRT for patients
withAKIremainsuncertainandnorecommendationscanbe
made beyond the traditional indications currently employed
in clinical practice. Well-designed randomised controlled
trials of early versus late RRT initiation can be achieved by
using the RIFLE consensus deﬁnition of AKI to ensure that
the early and late treatment arms are uniformly matched
with regards to severity of AKI and the use of validated
biomarkers of AKI which allows for early identiﬁcation and
randomisation of suitable patients with AKI. Furthermore,
treatment decisions should be made upon predetermined
criteria (biochemical or others). Finally, in order to reduceInternational Journal of Nephrology 13
allocation bias, patients who avoid RRT or die with AKI
having not received AKI should be included and analysed on
an intention-to-treat basis.
RegardingRRToptionsforAKI,inpatientswithanintact
peritoneal membrane and AKI, PD seems an acceptable
treatment choice with potential beneﬁts. A major barrier
towards more widespread use of PD is the lack of consensus
on optimal dose of PD and controversial application of data
inferred from studies in HD. Further studies of PD in AKI
addressing dose, importance of middle molecule clearance
and potential PD-related complications such as peritonitis-
risk, ﬂuid balance and increased protein loss are required for
this therapy to be accepted more widely by clinicians.
Finally, research around emerging AKI biomarkers is
promising in identifying markers of early renal injury, which
when combined with RIFLE/AKIN classiﬁcations may allow
timely recognition ofAKI to facilitate the muchneeded trials
of early versus late initiation of RRT.
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